{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:45:31Z","timestamp":1793839531665,"version":"4.6.1"},"reference-count":233,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Gobierno de Espa\u00f1a Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PID2020-120336RB-I00"],"award-info":[{"award-number":["PID2020-120336RB-I00"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004895","name":"European Social Fund Plus","doi-asserted-by":"publisher","award":["CD22\/00045"],"award-info":[{"award-number":["CD22\/00045"]}],"id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004895","name":"European Social Fund Plus","doi-asserted-by":"publisher","award":["CP21\/00025"],"award-info":[{"award-number":["CP21\/00025"]}],"id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"Federaci\u00f3n Espa\u00f1ola de Enfermedades Raras","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011596","name":"Generalitat Valenciana Conselleria d' Educaci\u00f3, Investigaci\u00f3, Cultura i Esport","doi-asserted-by":"publisher","award":["APOTIP\/2020\/011"],"award-info":[{"award-number":["APOTIP\/2020\/011"]}],"id":[{"id":"10.13039\/501100011596","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011596","name":"Generalitat Valenciana Conselleria d' Educaci\u00f3, Investigaci\u00f3, Cultura i Esport","doi-asserted-by":"publisher","award":["PROMETEO\/2019\/032"],"award-info":[{"award-number":["PROMETEO\/2019\/032"]}],"id":[{"id":"10.13039\/501100011596","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI21-00220"],"award-info":[{"award-number":["PI21-00220"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003359","name":"Generalitat Valenciana","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.phrs.2024.107058","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T04:31:13Z","timestamp":1704947473000},"page":"107058","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"special_numbering":"C","title":["Targeting systemic inflammation in metabolic disorders. A therapeutic candidate for the prevention of cardiovascular diseases?"],"prefix":"10.1016","volume":"200","author":[{"given":"Elena","family":"Domingo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Francisco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Piqueras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Jesus","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2024.107058_bib1","unstructured":"Network GBoDC. Global Burden of Disease Study 2019 (GBD 2019) Results. Seattle, United States: institute for Health Metrics and Evaluation (IHME). 2020."},{"issue":"10","key":"10.1016\/j.phrs.2024.107058_bib2","doi-asserted-by":"crossref","first-page":"e1332","DOI":"10.1016\/S2214-109X(19)30318-3","article-title":"World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions","volume":"7","author":"Group WCRCW","year":"2019","journal-title":"Lancet Glob. Health"},{"issue":"10053","key":"10.1016\/j.phrs.2024.107058_bib3","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0140-6736(16)31012-1","article-title":"Causes of Death C. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"388","author":"Mortality GBD","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.phrs.2024.107058_bib4","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41569-018-0144-3","article-title":"Targeting inflammation in CVD: advances and challenges","volume":"16","author":"Moore","year":"2019","journal-title":"Nat. Rev. Cardiol."},{"issue":"7","key":"10.1016\/j.phrs.2024.107058_bib5","first-page":"389","article-title":"Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities","volume":"16","author":"Back","year":"2019","journal-title":"Nat. Rev. Cardiol."},{"issue":"17","key":"10.1016\/j.phrs.2024.107058_bib6","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/j.jacc.2018.08.1043","article-title":"Inflammation, Immunity, and Infection in Atherothrombosis: JACC Review Topic of the Week","volume":"72","author":"Libby","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"8","key":"10.1016\/j.phrs.2024.107058_bib7","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/s41569-021-00668-4","article-title":"Therapeutic strategies targeting inflammation and immunity in atherosclerosis: how to proceed?","volume":"19","author":"Engelen","year":"2022","journal-title":"Nat. Rev. Cardiol."},{"issue":"5","key":"10.1016\/j.phrs.2024.107058_bib8","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1161\/ATVBAHA.123.316246","article-title":"Impact of impaired cholesterol homeostasis on neutrophils in atherosclerosis","volume":"43","author":"Tucker","year":"2023","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.phrs.2024.107058_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2022.100342","article-title":"Ten things to know about ten cardiovascular disease risk factors - 2022","volume":"10","author":"Bays","year":"2022","journal-title":"Am. J. Prev. Cardiol."},{"key":"10.1016\/j.phrs.2024.107058_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.biocel.2021.106066","article-title":"Primary hypercholesterolemia and development of cardiovascular disorders: cellular and molecular mechanisms involved in low-grade systemic inflammation and endothelial dysfunction","volume":"139","author":"Collado","year":"2021","journal-title":"Int J. Biochem Cell Biol."},{"issue":"5","key":"10.1016\/j.phrs.2024.107058_bib11","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2337\/dc15-2439","article-title":"Cardiovascular risk factor targets and cardiovascular disease event risk in diabetes: a pooling project of the atherosclerosis risk in communities study, multi-ethnic study of atherosclerosis, and jackson heart study","volume":"39","author":"Wong","year":"2016","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.phrs.2024.107058_bib12","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3390\/jcm8010018","article-title":"Novel immune features of the systemic inflammation associated with primary hypercholesterolemia: changes in cytokine\/chemokine profile, increased platelet and leukocyte activation","volume":"8","author":"Collado","year":"2018","journal-title":"J. Clin. Med."},{"issue":"5","key":"10.1016\/j.phrs.2024.107058_bib13","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3390\/jcm8050708","article-title":"Systemic inflammation in metabolic syndrome: increased platelet and leukocyte activation, and key role of CX(3)CL1\/CX(3)CR1 and CCL2\/CCR2 Axes in Arterial Platelet-Proinflammatory Monocyte Adhesion","volume":"8","author":"Marques","year":"2019","journal-title":"J. Clin. Med."},{"issue":"7","key":"10.1016\/j.phrs.2024.107058_bib14","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.3390\/biomedicines10071745","article-title":"Obesity and endothelial function","volume":"10","author":"Kajikawa","year":"2022","journal-title":"Biomedicines"},{"issue":"7","key":"10.1016\/j.phrs.2024.107058_bib15","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1053\/j.gastro.2020.02.020","article-title":"Metabolic inflammation-a role for hepatic inflammatory pathways as drivers of comorbidities in nonalcoholic fatty liver disease?","volume":"158","author":"Gehrke","year":"2020","journal-title":"Gastroenterology"},{"issue":"21 Suppl 1","key":"10.1016\/j.phrs.2024.107058_bib16","article-title":"Endothelial function: a critical determinant in atherosclerosis?","volume":"109","author":"Landmesser","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2024.107058_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106814","article-title":"The burden of hypercholesterolemia and ischemic heart disease in an ageing world","volume":"193","author":"Pirillo","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2024.107058_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/heartjnl-2022-321917","article-title":"Familial hypercholesterolaemia and emerging therapeutics","author":"Farias","year":"2023","journal-title":"Heart"},{"issue":"19","key":"10.1016\/j.phrs.2024.107058_bib19","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.jacc.2014.01.060","article-title":"The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies","volume":"63","author":"Sniderman","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.phrs.2024.107058_bib20","doi-asserted-by":"crossref","DOI":"10.1007\/s11886-019-1130-z","article-title":"Polygenic hypercholesterolemia and cardiovascular disease risk","volume":"21","author":"Sharifi","year":"2019","journal-title":"Curr. Cardiol. Rep."},{"issue":"4","key":"10.1016\/j.phrs.2024.107058_bib21","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/jamacardio.2019.5954","article-title":"Association of monogenic vs polygenic hypercholesterolemia with risk of atherosclerotic cardiovascular disease","volume":"5","author":"Trinder","year":"2020","journal-title":"JAMA Cardiol."},{"issue":"2","key":"10.1016\/j.phrs.2024.107058_bib22","doi-asserted-by":"crossref","first-page":"76","DOI":"10.4330\/wjc.v9.i2.76","article-title":"PCSK9 inhibitors: a new era of lipid lowering therapy","volume":"9","author":"Chaudhary","year":"2017","journal-title":"World J. Cardiol."},{"issue":"4","key":"10.1016\/j.phrs.2024.107058_bib23","first-page":"669","article-title":"Familial hypercholesterolemia","volume":"14","author":"Pejic","year":"2014","journal-title":"Ochsner J."},{"issue":"2","key":"10.1016\/j.phrs.2024.107058_bib24","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s11883-014-0482-5","article-title":"Familial hypercholesterolemia--epidemiology, diagnosis, and screening","volume":"17","author":"Singh","year":"2015","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.phrs.2024.107058_bib25","article-title":"Familial hypercholesterolaemia","volume":"3","author":"Defesche","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.phrs.2024.107058_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.00707","article-title":"Familial hypercholesterolemia: new horizons for diagnosis and effective management","volume":"9","author":"Mytilinaiou","year":"2018","journal-title":"Front. Pharm."},{"issue":"1","key":"10.1016\/j.phrs.2024.107058_bib27","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1614362","article-title":"Health effects of overweight and obesity in 195 Countries over 25 Years","volume":"377","author":"Afshin","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.phrs.2024.107058_bib28","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/ije\/dyu058","article-title":"Indices of relative weight and obesity","volume":"43","author":"Keys","year":"2014","journal-title":"Int. J. Epidemiol."},{"issue":"2","key":"10.1016\/j.phrs.2024.107058_bib29","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s13679-020-00375-0","article-title":"Metabolically healthy obesity: criteria, epidemiology, controversies, and consequences","volume":"9","author":"Tsatsoulis","year":"2020","journal-title":"Curr. Obes. Rep."},{"issue":"21","key":"10.1016\/j.phrs.2024.107058_bib30","doi-asserted-by":"crossref","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","article-title":"Obesity and cardiovascular disease: a scientific statement from the American Heart Association","volume":"143","author":"Powell-Wiley","year":"2021","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.phrs.2024.107058_bib31","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41573-021-00337-8","article-title":"Anti-obesity drug discovery: advances and challenges","volume":"21","author":"M\u00fcller","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2024.107058_bib32","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/6508709","article-title":"Simvastatin effects on inflammation and platelet activation markers in hypercholesterolemia","volume":"2018","author":"Barale","year":"2018","journal-title":"Biomed. Res. Int."},{"issue":"5","key":"10.1016\/j.phrs.2024.107058_bib33","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1586\/14779072.2015.1030395","article-title":"Evolocumab (AMG 145) for primary hypercholesterolemia","volume":"13","author":"Langslet","year":"2015","journal-title":"Expert Rev. Cardiovasc Ther."},{"key":"10.1016\/j.phrs.2024.107058_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00294","article-title":"Endothelial to mesenchymal transition represents a key link in the interaction between inflammation and endothelial dysfunction","volume":"9","author":"Cho","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2024.107058_bib35","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.cyto.2018.10.011","article-title":"Inflammatory biomarkers in patients in Simvastatin treatment: no effect of co-enzyme Q10 supplementation","volume":"113","author":"Hansen","year":"2019","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.phrs.2024.107058_bib36","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.arcmed.2016.01.002","article-title":"Postprandial changes in chemokines related to early atherosclerotic processes in familial hypercholesterolemic subjects: a preliminary study","volume":"47","author":"Cortes","year":"2016","journal-title":"Arch. Med. Res."},{"issue":"22","key":"10.1016\/j.phrs.2024.107058_bib37","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1111\/bph.13805","article-title":"Vascular inflammation and low-density lipoproteins: is cholesterol the link? A lesson from the clinical trials","volume":"174","author":"Catapano","year":"2017","journal-title":"Br. J. Pharm."},{"issue":"10","key":"10.1016\/j.phrs.2024.107058_bib38","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.amjhyper.2006.03.016","article-title":"Relationship of circulating biomarkers of inflammation and hemostasis with preclinical atherosclerotic burden in nonsmoking hypercholesterolemic men","volume":"19","author":"Chironi","year":"2006","journal-title":"Am. J. Hypertens."},{"issue":"2","key":"10.1016\/j.phrs.2024.107058_bib39","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.atherosclerosis.2007.08.014","article-title":"Primed polymorphonuclear leukocytes constitute a possible link between inflammation and oxidative stress in hyperlipidemic patients","volume":"197","author":"Mazor","year":"2008","journal-title":"Atherosclerosis"},{"issue":"10","key":"10.1016\/j.phrs.2024.107058_bib40","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1161\/ATVBAHA.120.316389","article-title":"Hypercholesterolemia impairs clearance of neutrophil extracellular traps and promotes inflammation and atherosclerotic plaque progression","volume":"41","author":"Dhawan","year":"2021","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"2","key":"10.1016\/j.phrs.2024.107058_bib41","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.atherosclerosis.2014.10.106","article-title":"Pro-inflammatory monocyte-macrophage polarization imbalance in human hypercholesterolemia and atherosclerosis","volume":"237","author":"Fadini","year":"2014","journal-title":"Atherosclerosis"},{"issue":"20","key":"10.1016\/j.phrs.2024.107058_bib42","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1093\/eurheartj\/ehx002","article-title":"PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia","volume":"38","author":"Bernelot Moens","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2024.107058_bib43","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.atherosclerosis.2016.11.031","article-title":"Altered leukocyte distribution under hypercholesterolemia: a cross-sectional study in children with familial hypercholesterolemia","volume":"256","author":"Christensen","year":"2017","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.phrs.2024.107058_bib44","doi-asserted-by":"crossref","first-page":"737","DOI":"10.5551\/jat.31088","article-title":"HMGB1Modulates the Treg\/Th17 Ratio in Atherosclerotic Patients","volume":"23","author":"Ding","year":"2016","journal-title":"J. Atheroscler. Thromb."},{"issue":"4","key":"10.1016\/j.phrs.2024.107058_bib45","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1161\/CIRCRESAHA.115.306427","article-title":"Adaptive response of T and B cells in atherosclerosis","volume":"118","author":"Ketelhuth","year":"2016","journal-title":"Circ. Res."},{"key":"10.1016\/j.phrs.2024.107058_bib46","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/978-3-319-48382-5_15","article-title":"Endothelial dysfunction in obesity","volume":"960","author":"Engin","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.phrs.2024.107058_bib47","doi-asserted-by":"crossref","DOI":"10.1186\/s13098-019-0468-0","article-title":"Cardiovascular risk and obesity","volume":"11","author":"Cercato","year":"2019","journal-title":"Diabetol. Metab. Syndr."},{"issue":"2","key":"10.1016\/j.phrs.2024.107058_bib48","doi-asserted-by":"crossref","first-page":"150","DOI":"10.2478\/v10039-009-0035-2","article-title":"Role of adipokines in complications related to obesity: a review","volume":"54","author":"Gnaci\u0144ska","year":"2009","journal-title":"Adv. Med. Sci."},{"key":"10.1016\/j.phrs.2024.107058_bib49","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.biochi.2023.04.008","article-title":"Adipokines in obesity and metabolic-related-diseases","volume":"212","author":"Pestel","year":"2023","journal-title":"Biochimie"},{"key":"10.1016\/j.phrs.2024.107058_bib50","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3389\/fendo.2013.00071","article-title":"Adipokines mediate inflammation and insulin resistance","volume":"4","author":"Kwon","year":"2013","journal-title":"Front. Endocrinol."},{"issue":"8","key":"10.1016\/j.phrs.2024.107058_bib51","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1210\/jc.2007-2630","article-title":"CC chemokine and CC chemokine receptor profiles in visceral and subcutaneous adipose tissue are altered in human obesity","volume":"93","author":"Huber","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.phrs.2024.107058_bib52","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1038\/s41366-018-0102-5","article-title":"Upregulation of angiostatic chemokines IP-10\/CXCL10 and I-TAC\/CXCL11 in human obesity and their implication for adipose tissue angiogenesis","volume":"42","author":"Hueso","year":"2018","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.phrs.2024.107058_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1154158","article-title":"CCL17 and CCL22 chemokines are upregulated in human obesity and play a role in vascular dysfunction","volume":"14","author":"Hueso","year":"2023","journal-title":"Front. Endocrinol."},{"issue":"3","key":"10.1016\/j.phrs.2024.107058_bib54","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41423-021-00804-7","article-title":"Resident and migratory adipose immune cells control systemic metabolism and thermogenesis","volume":"19","author":"Man","year":"2022","journal-title":"Cell Mol. Immunol."},{"key":"10.1016\/j.phrs.2024.107058_bib55","article-title":"Adipose tissue macrophages as potential targets for obesity and metabolic diseases","volume":"14","author":"Li","year":"2023","journal-title":"Front. Immunol."},{"issue":"16","key":"10.1016\/j.phrs.2024.107058_bib56","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.288.16.2008","article-title":"Platelet activation in obese women: role of inflammation and oxidant stress","volume":"288","author":"Dav\u00ec","year":"2002","journal-title":"Jama"},{"issue":"3","key":"10.1016\/j.phrs.2024.107058_bib57","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.numecd.2006.09.010","article-title":"sP-selectin plasma levels in obesity: association with insulin resistance and related metabolic and prothrombotic factors","volume":"18","author":"De Pergola","year":"2008","journal-title":"Nutr. Metab. Cardiovasc Dis."},{"issue":"12","key":"10.1016\/j.phrs.2024.107058_bib58","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1161\/01.CIR.0000142055.53122.FA","article-title":"Circulating mononuclear cells in the obese are in a proinflammatory state","volume":"110","author":"Ghanim","year":"2004","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.phrs.2024.107058_bib59","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2337\/db11-1065","article-title":"Morbidly obese human subjects have increased peripheral blood CD4+ T cells with skewing toward a Treg- and Th2-dominated phenotype","volume":"61","author":"van der Weerd","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.phrs.2024.107058_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.675018","article-title":"Effects of morbid obesity and metabolic syndrome on the composition of circulating immune subsets","volume":"12","author":"Wijngaarden","year":"2021","journal-title":"Front Immunol."},{"key":"10.1016\/j.phrs.2024.107058_bib61","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.clim.2016.01.007","article-title":"Alteration of natural killer cell phenotype and function in obese individuals","volume":"177","author":"Viel","year":"2017","journal-title":"Clin. Immunol."},{"issue":"2","key":"10.1016\/j.phrs.2024.107058_bib62","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s12026-018-8989-4","article-title":"Impaired natural killer cell subset phenotypes in human obesity","volume":"66","author":"B\u00e4hr","year":"2018","journal-title":"Immunol. Res."},{"issue":"4 Pt 2","key":"10.1016\/j.phrs.2024.107058_bib63","first-page":"H1725","article-title":"Cytokine-induced leukocyte rolling in mouse cremaster muscle arterioles in P-selectin dependent","volume":"272","author":"Thorlacius","year":"1997","journal-title":"Am. J. Physiol."},{"issue":"3 Pt 2","key":"10.1016\/j.phrs.2024.107058_bib64","first-page":"H1391","article-title":"TNF-alpha induces selectin-mediated leukocyte rolling in mouse cremaster muscle arterioles","volume":"272","author":"Kunkel","year":"1997","journal-title":"Am. J. Physiol."},{"issue":"7","key":"10.1016\/j.phrs.2024.107058_bib65","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1161\/01.ATV.13.7.1013","article-title":"Oxidized LDL-induced leukocyte\/endothelium interaction in vivo involves the receptor for platelet-activating factor","volume":"13","author":"Lehr","year":"1993","journal-title":"Arterioscler. Thromb."},{"issue":"16","key":"10.1016\/j.phrs.2024.107058_bib66","doi-asserted-by":"crossref","first-page":"7688","DOI":"10.1073\/pnas.91.16.7688","article-title":"Vitamin C prevents cigarette smoke-induced leukocyte aggregation and adhesion to endothelium in vivo","volume":"91","author":"Lehr","year":"1994","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"2","key":"10.1016\/j.phrs.2024.107058_bib67","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1182\/blood-2003-08-2974","article-title":"Direct evidence of leukocyte adhesion in arterioles by angiotensin II","volume":"104","author":"Alvarez","year":"2004","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.phrs.2024.107058_bib68","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.imbio.2011.05.010","article-title":"A glimpse on the phenomenon of macrophage polarization during atherosclerosis","volume":"216","author":"Pello","year":"2011","journal-title":"Immunobiology"},{"key":"10.1016\/j.phrs.2024.107058_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.679797","article-title":"Macrophage plasticity and atherosclerosis therapy","volume":"8","author":"Lin","year":"2021","journal-title":"Front. Mol. Biosci."},{"issue":"4","key":"10.1016\/j.phrs.2024.107058_bib70","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/ehjcvp\/pvz022","article-title":"PCSK9 and inflammation: a review of experimental and clinical evidence","volume":"5","author":"Momtazi-Borojeni","year":"2019","journal-title":"Eur. Heart J. Cardiovasc Pharm."},{"issue":"3","key":"10.1016\/j.phrs.2024.107058_bib71","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0123088","article-title":"Oxidized low-density lipoprotein contributes to atherogenesis via Co-activation of macrophages and mast cells","volume":"10","author":"Chen","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.phrs.2024.107058_bib72","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1161\/CIRCRESAHA.115.306301","article-title":"Endothelial cell dysfunction and the pathobiology of atherosclerosis","volume":"118","author":"Gimbrone","year":"2016","journal-title":"Circ. Res."},{"issue":"8","key":"10.1016\/j.phrs.2024.107058_bib73","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1002\/jcp.26466","article-title":"Oxidative burden in familial hypercholesterolemia","volume":"233","author":"Mollazadeh","year":"2018","journal-title":"J. Cell Physiol."},{"issue":"1","key":"10.1016\/j.phrs.2024.107058_bib74","doi-asserted-by":"crossref","DOI":"10.1186\/s12944-017-0470-1","article-title":"Enhanced status of inflammation and endothelial activation in subjects with familial hypercholesterolaemia and their related unaffected family members: a case control study","volume":"16","author":"Rahman","year":"2017","journal-title":"Lipids Health Dis."},{"issue":"2","key":"10.1016\/j.phrs.2024.107058_bib75","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.metabol.2009.07.026","article-title":"Increased oxidative stress levels and normal antioxidant enzyme activity in circulating mononuclear cells from patients of familial hypercholesterolemia","volume":"59","author":"Real","year":"2010","journal-title":"Metabolism"},{"issue":"1-2","key":"10.1016\/j.phrs.2024.107058_bib76","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cccn.2005.04.020","article-title":"Mechanisms of endothelial dysfunction in obesity","volume":"360","author":"Avogaro","year":"2005","journal-title":"Clin. Chim. Acta"},{"issue":"4","key":"10.1016\/j.phrs.2024.107058_bib77","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1253\/circj.CJ-08-1169","article-title":"Endothelial dysfunction: the first step toward coronary arteriosclerosis","volume":"73","author":"Vanhoutte","year":"2009","journal-title":"Circ. J."},{"issue":"11","key":"10.1016\/j.phrs.2024.107058_bib78","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1038\/oby.2003.174","article-title":"Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease","volume":"11","author":"Caballero","year":"2003","journal-title":"Obes. Res."},{"issue":"5","key":"10.1016\/j.phrs.2024.107058_bib79","first-page":"575","article-title":"Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms","volume":"34","author":"Petrie","year":"2018","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.phrs.2024.107058_bib80","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1146\/annurev-immunol-031210-101322","article-title":"Inflammatory mechanisms in obesity","volume":"29","author":"Gregor","year":"2011","journal-title":"Annu Rev. Immunol."},{"issue":"12","key":"10.1016\/j.phrs.2024.107058_bib81","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1172\/JCI200319451","article-title":"Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance","volume":"112","author":"Xu","year":"2003","journal-title":"J. Clin. Investig."},{"issue":"6","key":"10.1016\/j.phrs.2024.107058_bib82","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/j.1538-7836.2011.04285.x","article-title":"Translational evidence of endothelial damage in obese individuals: inflammatory and prothrombotic responses","volume":"9","author":"Hanzu","year":"2011","journal-title":"J. Thromb. Haemost."},{"issue":"12","key":"10.1016\/j.phrs.2024.107058_bib83","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.febslet.2008.04.037","article-title":"High molecular weight adiponectin activates AMPK and suppresses cytokine-induced NF-kappaB activation in vascular endothelial cells","volume":"582","author":"Hattori","year":"2008","journal-title":"FEBS Lett."},{"issue":"5","key":"10.1016\/j.phrs.2024.107058_bib84","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1042\/CS20070347","article-title":"Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention","volume":"114","author":"Zhu","year":"2008","journal-title":"Clin. Sci."},{"issue":"7","key":"10.1016\/j.phrs.2024.107058_bib85","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1172\/JCI29126","article-title":"Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome","volume":"116","author":"Kadowaki","year":"2006","journal-title":"J. Clin. Investig."},{"issue":"1","key":"10.1016\/j.phrs.2024.107058_bib86","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.atherosclerosis.2006.03.003","article-title":"Leptin and atherosclerosis","volume":"189","author":"Beltowski","year":"2006","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.phrs.2024.107058_bib87","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1161\/01.CIR.0000084503.91330.49","article-title":"Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction","volume":"108","author":"Verma","year":"2003","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.phrs.2024.107058_bib88","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/cvr\/cvx086","article-title":"New insights into the role of adipose tissue in thrombosis","volume":"113","author":"Vilahur","year":"2017","journal-title":"Cardiovasc. Res."},{"issue":"1","key":"10.1016\/j.phrs.2024.107058_bib89","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/oby.2011.299","article-title":"Overproduction of angiotensinogen from adipose tissue induces adipose inflammation, glucose intolerance, and insulin resistance","volume":"20","author":"Kalupahana","year":"2012","journal-title":"Obesity"},{"key":"10.1016\/j.phrs.2024.107058_bib90","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.freeradbiomed.2020.02.002","article-title":"Angiotensin II and leukocyte trafficking: new insights for an old vascular mediator. Role of redox-signaling pathways","volume":"157","author":"Piqueras","year":"2020","journal-title":"Free Radic. Biol. Med."},{"issue":"1","key":"10.1016\/j.phrs.2024.107058_bib91","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/ATVBAHA.112.254870","article-title":"Arterial and venous endothelia display differential functional fractalkine (CX3CL1) expression by angiotensin-II","volume":"33","author":"Rius","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"25","key":"10.1016\/j.phrs.2024.107058_bib92","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: a report of the american college of cardiology\/american heart association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.phrs.2024.107058_bib93","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1210\/er.2017-00253","article-title":"The science of obesity management: an endocrine society scientific statement","volume":"39","author":"Bray","year":"2018","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.phrs.2024.107058_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111789","article-title":"Diets and drugs for weight loss and health in obesity - An update","volume":"140","author":"Aaseth","year":"2021","journal-title":"Biomed. Pharm."},{"issue":"4","key":"10.1016\/j.phrs.2024.107058_bib95","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3390\/pathogens12040627","article-title":"Familial hypercholesterolemia and acute coronary syndromes: the microbiota-immunity axis in the new diagnostic and prognostic frontiers","volume":"12","author":"Piccioni","year":"2023","journal-title":"Pathogens"},{"issue":"19","key":"10.1016\/j.phrs.2024.107058_bib96","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.3390\/nu14193985","article-title":"Beneficial effects of anti-inflammatory diet in modulating gut microbiota and controlling obesity","volume":"14","author":"Bagheri","year":"2022","journal-title":"Nutrients"},{"issue":"9","key":"10.1016\/j.phrs.2024.107058_bib97","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1161\/CIRCGEN.119.002314","article-title":"Gut microbiome and response to cardiovascular drugs","volume":"12","author":"Tuteja","year":"2019","journal-title":"Circ. Genom. Precis Med"},{"issue":"14","key":"10.1016\/j.phrs.2024.107058_bib98","doi-asserted-by":"crossref","first-page":"e587","DOI":"10.1161\/CIRCULATIONAHA.115.020701","article-title":"Heterozygous familial hypercholesterolemia","volume":"133","author":"Onorato","year":"2016","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.phrs.2024.107058_bib99","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.pcad.2016.07.006","article-title":"Familial hypercholesterolemia: advances in recognition and therapy","volume":"59","author":"Cartier","year":"2016","journal-title":"Prog. Cardiovasc Dis."},{"issue":"10160","key":"10.1016\/j.phrs.2024.107058_bib100","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Frias","year":"2018","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.phrs.2024.107058_bib101","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"10148","key":"10.1016\/j.phrs.2024.107058_bib102","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"O'Neil","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.phrs.2024.107058_bib103","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.3390\/ijms24032313","article-title":"Overview of cellular and soluble mediators in systemic inflammation associated with non-alcoholic fatty liver disease","volume":"24","author":"Marques","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"17","key":"10.1016\/j.phrs.2024.107058_bib104","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/eurheartj\/ehm247","article-title":"Protective effect of atorvastatin on acute systemic inflammation-induced endothelial dysfunction in hypercholesterolaemic subjects","volume":"28","author":"Vlachopoulos","year":"2007","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2024.107058_bib105","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.atherosclerosis.2017.04.004","article-title":"Effects of atorvastatin and diet interventions on atherosclerotic plaque inflammation and [(18)F]FDG uptake in Ldlr(-\/-)Apob(100\/100) mice","volume":"263","author":"Hellberg","year":"2017","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.phrs.2024.107058_bib106","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.pathophys.2004.07.001","article-title":"Direct inhibition by a statin of TNFalpha-induced leukocyte recruitment in rat pial venules - in vivo confocal microscopic study","volume":"11","author":"Obama","year":"2004","journal-title":"Pathophysiology"},{"issue":"12","key":"10.1016\/j.phrs.2024.107058_bib107","doi-asserted-by":"crossref","DOI":"10.1007\/s11883-021-00977-6","article-title":"Statins and inflammation","volume":"23","author":"Satny","year":"2021","journal-title":"Curr. Atheroscler. Rep."},{"issue":"2","key":"10.1016\/j.phrs.2024.107058_bib108","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.it.2006.12.003","article-title":"Statins and the vascular endothelial inflammatory response","volume":"28","author":"Greenwood","year":"2007","journal-title":"Trends Immunol."},{"issue":"1-2","key":"10.1016\/j.phrs.2024.107058_bib109","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0009-8981(03)00335-8","article-title":"Atorvastatin reduces interleukin-6 plasma concentration and adipocyte secretion of hypercholesterolemic rabbits","volume":"336","author":"Zhao","year":"2003","journal-title":"Clin. Chim. Acta"},{"issue":"3","key":"10.1016\/j.phrs.2024.107058_bib110","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2217\/fca-2017-0019","article-title":"PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-\u03b2\/\u03b4 and PPAR-\u03b3","volume":"13","author":"Han","year":"2017","journal-title":"Future Cardiol."},{"issue":"11","key":"10.1016\/j.phrs.2024.107058_bib111","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1161\/01.CIR.0000086460.55494.AF","article-title":"Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin","volume":"108","author":"Kleemann","year":"2003","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.phrs.2024.107058_bib112","doi-asserted-by":"crossref","first-page":"H2046","DOI":"10.1152\/ajpheart.00133.2008","article-title":"Effects of rosuvastatin on cardiovascular morphology and function in an ApoE-knockout mouse model of atherosclerosis","volume":"295","author":"Gr\u00f6nros","year":"2008","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"6","key":"10.1016\/j.phrs.2024.107058_bib113","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/aps.2013.8","article-title":"Simvastatin suppresses vascular inflammation and atherosclerosis in ApoE(-\/-) mice by downregulating the HMGB1-RAGE axis","volume":"34","author":"Liu","year":"2013","journal-title":"Acta Pharm. Sin."},{"issue":"1","key":"10.1016\/j.phrs.2024.107058_bib114","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0021-9150(01)00547-0","article-title":"Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells","volume":"160","author":"Hern\u00e1ndez-Presa","year":"2002","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.phrs.2024.107058_bib115","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0021-9150(99)00193-8","article-title":"Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells.","volume":"147","author":"Ortego","year":"1999","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.phrs.2024.107058_bib116","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/FJC.0b013e318211703b","article-title":"The effect of ezetimibe and simvastatin on monocyte cytokine release in patients with isolated hypercholesterolemia","volume":"57","author":"Krysiak","year":"2011","journal-title":"J. Cardiovasc Pharmacol."},{"issue":"6","key":"10.1016\/j.phrs.2024.107058_bib117","first-page":"725","article-title":"Different effects of simvastatin on ex vivo monocyte cytokine release in patients with hypercholesterolemia and impaired glucose tolerance","volume":"61","author":"Krysiak","year":"2010","journal-title":"J. Physiol. Pharmacol."},{"issue":"2","key":"10.1016\/j.phrs.2024.107058_bib118","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0021-9150(03)00193-X","article-title":"Soluble intercellular adhesion molecule-1 and interleukin-6 levels reflect endothelial dysfunction in patients with primary hypercholesterolaemia treated with atorvastatin","volume":"169","author":"Nawawi","year":"2003","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.phrs.2024.107058_bib119","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1161\/01.CIR.0000080895.05158.8B","article-title":"Statins promote potent systemic antioxidant effects through specific inflammatory pathways","volume":"108","author":"Shishehbor","year":"2003","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.phrs.2024.107058_bib120","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.2169\/internalmedicine.51.6771","article-title":"Effect of rosuvastatin on ROCK activity, endothelial function, and inflammation in Asian patients with atherosclerosis","volume":"51","author":"Liu","year":"2012","journal-title":"Intern. Med."},{"issue":"37","key":"10.1016\/j.phrs.2024.107058_bib121","doi-asserted-by":"crossref","first-page":"24266","DOI":"10.1074\/jbc.273.37.24266","article-title":"Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase","volume":"273","author":"Laufs","year":"1998","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.phrs.2024.107058_bib122","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1042\/CS20020293","article-title":"Correlates of endothelial function and their relationship with inflammation in patients with familial hypercholesterolaemia","volume":"104","author":"van Haelst","year":"2003","journal-title":"Clin. Sci."},{"issue":"1","key":"10.1016\/j.phrs.2024.107058_bib123","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jacc.2020.05.016","article-title":"Association of statin use with disability-free survival and cardiovascular disease among healthy older adults","volume":"76","author":"Zhou","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.phrs.2024.107058_bib124","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00228-021-03239-1","article-title":"Comparison of statins for primary prevention of cardiovascular disease and persistent physical disability in older adults","volume":"78","author":"Zhou","year":"2022","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2024.107058_bib125","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/1074248412444463","article-title":"Effects of statin monotherapy versus statin plus ezetimibe combination on serum uric acid levels","volume":"18","author":"Moutzouri","year":"2013","journal-title":"J. Cardiovasc Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.phrs.2024.107058_bib126","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/2040622316672544","article-title":"Ezetimibe: an update on its clinical usefulness in specific patient groups","volume":"8","author":"Hammersley","year":"2017","journal-title":"Ther. Adv. Chronic Dis."},{"issue":"11","key":"10.1016\/j.phrs.2024.107058_bib127","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0142430","article-title":"Ezetimibe attenuates atherosclerosis associated with lipid reduction and inflammation inhibition","volume":"10","author":"Tie","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2024.107058_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110388","article-title":"New possible pharmacological targets for statins and ezetimibe","volume":"129","author":"Niedzielski","year":"2020","journal-title":"Biomed. Pharm."},{"issue":"7","key":"10.1016\/j.phrs.2024.107058_bib129","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2967\/jnumed.116.177279","article-title":"Evaluation of Antiatherogenic Properties of Ezetimibe Using (3)H-Labeled Low-Density-Lipoprotein Cholesterol and (99m)Tc-cAbVCAM1-5 SPECT in ApoE(-\/-) Mice Fed the Paigen Diet","volume":"58","author":"Dumas","year":"2017","journal-title":"J. Nucl. Med."},{"issue":"8","key":"10.1016\/j.phrs.2024.107058_bib130","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1111\/j.1476-5381.2008.00091.x","article-title":"Ezetimibe reduces plaque inflammation in a rabbit model of atherosclerosis and inhibits monocyte migration in addition to its lipid-lowering effect","volume":"156","author":"G\u00f3mez-Garre","year":"2009","journal-title":"Br. J. Pharm."},{"issue":"1","key":"10.1016\/j.phrs.2024.107058_bib131","first-page":"32","article-title":"Familial hypercholesterolemia: review of diagnosis, screening, and treatment","volume":"62","author":"Turgeon","year":"2016","journal-title":"Can. Fam. Physician"},{"issue":"7","key":"10.1016\/j.phrs.2024.107058_bib132","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1080\/14779072.2021.1940959","article-title":"Rosuvastatin and ezetimibe for the treatment of dyslipidemia and hypercholesterolemia","volume":"19","author":"Boutari","year":"2021","journal-title":"Expert Rev. Cardiovasc Ther."},{"issue":"3","key":"10.1016\/j.phrs.2024.107058_bib133","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s11596-018-1892-3","article-title":"Ezetimibe protects endothelial cells against oxidative stress through Akt\/GSK-3\u03b2 pathway","volume":"38","author":"Qin","year":"2018","journal-title":"Curr. Med. Sci."},{"issue":"2","key":"10.1016\/j.phrs.2024.107058_bib134","doi-asserted-by":"crossref","first-page":"114","DOI":"10.5603\/EP.2015.0017","article-title":"Comparison of the effects of short-term hypolipidaemic treatment on plasma adipokine levels in men and women with isolated hypercholesterolaemia","volume":"66","author":"Krysiak","year":"2015","journal-title":"Endokrynol. Pol."},{"issue":"8","key":"10.1016\/j.phrs.2024.107058_bib135","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1185\/030079904125004213","article-title":"Pharmacodynamic interaction between ezetimibe and rosuvastatin","volume":"20","author":"Kosoglou","year":"2004","journal-title":"Curr. Med. Res. Opin."},{"issue":"3","key":"10.1016\/j.phrs.2024.107058_bib136","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s40256-016-0205-0","article-title":"Defining the place of Ezetimibe\/Atorvastatin in the management of hyperlipidemia","volume":"17","author":"Ferreira","year":"2017","journal-title":"Am. J. Cardiovasc Drugs"},{"issue":"8","key":"10.1016\/j.phrs.2024.107058_bib137","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1080\/14656566.2019.1594776","article-title":"Evaluating the efficacy and safety of atorvastatin + ezetimibe in a fixed-dose combination for the treatment of hypercholesterolemia","volume":"20","author":"Ma","year":"2019","journal-title":"Expert Opin. Pharm."},{"key":"10.1016\/j.phrs.2024.107058_bib138","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/2995602","article-title":"Ezetimibe improves rosuvastatin effects on inflammation and vascular endothelial function in acute coronary syndrome patients undergoing PCI","volume":"2021","author":"Sun","year":"2021","journal-title":"J. Inter. Cardiol."},{"issue":"3","key":"10.1016\/j.phrs.2024.107058_bib139","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1536\/ihj.14-311","article-title":"Effect of combination therapy of ezetimibe and rosuvastatin on regression of coronary atherosclerosis in patients with coronary artery disease","volume":"56","author":"Masuda","year":"2015","journal-title":"Int. Heart J."},{"issue":"4","key":"10.1016\/j.phrs.2024.107058_bib140","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3390\/ph16040577","article-title":"Inclisiran, low-density lipoprotein cholesterol and lipoprotein (a)","volume":"16","author":"Katsiki","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.phrs.2024.107058_bib141","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112460","article-title":"Beneficial effects of PCSK9 inhibition with alirocumab in familial hypercholesterolemia involve modulation of new immune players","volume":"145","author":"Marques","year":"2022","journal-title":"Biomed. Pharm."},{"issue":"1","key":"10.1016\/j.phrs.2024.107058_bib142","article-title":"Therapeutic efficacy and safety of PCSK9-monoclonal antibodies on familial hypercholesterolemia and statin-intolerant patients: a meta-analysis of 15 randomized controlled trials","volume":"7","author":"Qian","year":"2017","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.phrs.2024.107058_bib143","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1093\/cvr\/cvaa212","article-title":"Inclisiran for the treatment of hypercholesterolaemia: implications and unanswered questions from the ORION trials","volume":"116","author":"Cupido","year":"2020","journal-title":"Cardiovasc. Res."},{"issue":"8","key":"10.1016\/j.phrs.2024.107058_bib144","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jacc.2017.11.069","article-title":"PCSK9 as a positive modulator of platelet activation","volume":"71","author":"Camera","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2024.107058_bib145","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.atherosclerosis.2016.07.910","article-title":"PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement","volume":"253","author":"Ferri","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2024.107058_bib146","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.atherosclerosis.2017.04.023","article-title":"New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4\/NF-kappaB pathway","volume":"262","author":"Tang","year":"2017","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.phrs.2024.107058_bib147","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s10753-022-01715-z","article-title":"PCSK9 promotes endothelial dysfunction during sepsis via the TLR4\/MyD88\/NF-\u03baB and NLRP3 pathways","volume":"46","author":"Huang","year":"2023","journal-title":"Inflammation"},{"issue":"1-2","key":"10.1016\/j.phrs.2024.107058_bib148","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s11010-011-1028-6","article-title":"PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl\/Bax-caspase9-caspase3 pathway","volume":"359","author":"Wu","year":"2012","journal-title":"Mol. Cell Biochem."},{"key":"10.1016\/j.phrs.2024.107058_bib149","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ijcard.2016.10.084","article-title":"Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: the PCSK9-REACT study","volume":"227","author":"Navarese","year":"2017","journal-title":"Int. J. Cardiol."},{"issue":"1","key":"10.1016\/j.phrs.2024.107058_bib150","doi-asserted-by":"crossref","first-page":"76","DOI":"10.5551\/jat.25841","article-title":"The relationship between the plasma PCSK9 levels and platelet indices in patients with stable coronary artery disease","volume":"22","author":"Li","year":"2015","journal-title":"J. Atheroscler. Thromb."},{"issue":"12","key":"10.1016\/j.phrs.2024.107058_bib151","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.jacc.2017.07.743","article-title":"Relationship of PCSK9 and urinary thromboxane excretion to cardiovascular events in patients with atrial fibrillation","volume":"70","author":"Pastori","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"issue":"15","key":"10.1016\/j.phrs.2024.107058_bib152","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000033026","article-title":"Association of serum PCSK9 levels with platelet function in patients with acute coronary syndromes","volume":"102","author":"Wang","year":"2023","journal-title":"Medicine"},{"issue":"4","key":"10.1016\/j.phrs.2024.107058_bib153","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/cvr\/cvv178","article-title":"Cross-talk between LOX-1 and PCSK9 in vascular tissues","volume":"107","author":"Ding","year":"2015","journal-title":"Cardiovasc. Res."},{"issue":"20","key":"10.1016\/j.phrs.2024.107058_bib154","doi-asserted-by":"crossref","first-page":"11179","DOI":"10.3390\/ijms222011179","article-title":"Platelet-Derived PCSK9 is associated with LDL metabolism and modulates atherothrombotic mechanisms in coronary artery disease","volume":"22","author":"Petersen-Uribe","year":"2021","journal-title":"Int J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.phrs.2024.107058_bib155","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jacl.2014.07.001","article-title":"Relation of circulating PCSK9 concentration to fibrinogen in patients with stable coronary artery disease","volume":"8","author":"Zhang","year":"2014","journal-title":"J. Clin. Lipido"},{"issue":"2","key":"10.1016\/j.phrs.2024.107058_bib156","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.numecd.2019.09.012","article-title":"Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody: a 12-month follow-up","volume":"30","author":"Barale","year":"2020","journal-title":"Nutr. Metab. Cardiovasc Dis."},{"issue":"13","key":"10.1016\/j.phrs.2024.107058_bib157","doi-asserted-by":"crossref","first-page":"7193","DOI":"10.3390\/ijms22137193","article-title":"Proprotein convertase subtilisin kexin type 9 inhibitors reduce platelet activation modulating ox-LDL Pathways","volume":"22","author":"Cammisotto","year":"2021","journal-title":"Int J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.phrs.2024.107058_bib158","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.atherosclerosis.2014.04.001","article-title":"Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease","volume":"234","author":"Li","year":"2014","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.phrs.2024.107058_bib159","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/cvr\/cvaa077","article-title":"Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin\/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1","volume":"117","author":"Landmesser","year":"2021","journal-title":"Cardiovasc. Res."},{"issue":"6","key":"10.1016\/j.phrs.2024.107058_bib160","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1177\/2047487318815320","article-title":"Long-term exposure to air pollution raises circulating levels of proprotein convertase subtilisin\/kexin type 9 in obese individuals","volume":"26","author":"Macchi","year":"2019","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"1","key":"10.1016\/j.phrs.2024.107058_bib161","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-022-01542-4","article-title":"PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis","volume":"21","author":"Wang","year":"2022","journal-title":"Cardiovasc Diabetol."},{"issue":"32","key":"10.1016\/j.phrs.2024.107058_bib162","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1093\/eurheartj\/ehac360","article-title":"The absolute cardiovascular benefits of PCSK9 inhibitors and ezetimibe added to maximally tolerated statin therapy depend on individual baseline cardiovascular risk","volume":"43","author":"Liuzzo","year":"2022","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.phrs.2024.107058_bib163","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2337\/cd20-0038","article-title":"Bempedoic Acid: A Novel LDL cholesterol-lowering agent","volume":"38","author":"Shriver","year":"2020","journal-title":"Clin. Diabetes"},{"issue":"15","key":"10.1016\/j.phrs.2024.107058_bib164","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N. Engl. J. Med"},{"issue":"8","key":"10.1016\/j.phrs.2024.107058_bib165","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1194\/jlr.M035212","article-title":"ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK","volume":"54","author":"Filippov","year":"2013","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.phrs.2024.107058_bib166","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol. Metab."},{"issue":"6","key":"10.1016\/j.phrs.2024.107058_bib167","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133429","article-title":"Semaglutide lowers body weight in rodents via distributed neural pathways","volume":"5","author":"Gabery","year":"2020","journal-title":"JCI Insight"},{"issue":"4","key":"10.1016\/j.phrs.2024.107058_bib168","first-page":"342","article-title":"Role of prohormone convertases in the tissue-specific processing of proglucagon","volume":"10","author":"Dhanvantari","year":"1996","journal-title":"Mol. Endocrinol."},{"issue":"10","key":"10.1016\/j.phrs.2024.107058_bib169","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1073\/pnas.84.10.3434","article-title":"Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line","volume":"84","author":"Drucker","year":"1987","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.phrs.2024.107058_bib170","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol. Metab."},{"issue":"7","key":"10.1016\/j.phrs.2024.107058_bib171","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41574-018-0016-2","article-title":"Glucagon-like peptide 1 in health and disease","volume":"14","author":"Andersen","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"issue":"4","key":"10.1016\/j.phrs.2024.107058_bib172","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.2337\/db13-1440","article-title":"Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model","volume":"63","author":"Richards","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.phrs.2024.107058_bib173","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2018.00672","article-title":"Pleiotropic effects of GLP-1 and analogs on cell signaling, metabolism, and function","volume":"9","author":"Rowlands","year":"2018","journal-title":"Front. Endocrinol."},{"issue":"1","key":"10.1016\/j.phrs.2024.107058_bib174","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled Trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.phrs.2024.107058_bib175","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.diabres.2014.01.019","article-title":"Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: a prospective study","volume":"104","author":"D\u00edaz-Soto","year":"2014","journal-title":"Diabetes Res. Clin. Pr."},{"issue":"5","key":"10.1016\/j.phrs.2024.107058_bib176","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1042\/CS20160803","article-title":"GLP-1 analogue-induced weight loss does not improve obesity-induced AT dysfunction","volume":"131","author":"Pastel","year":"2017","journal-title":"Clin. Sci."},{"issue":"9 Pt B","key":"10.1016\/j.phrs.2024.107058_bib177","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1016\/j.bbadis.2018.05.012","article-title":"GLP-1 receptor agonists and reduction of cardiometabolic risk: potential underlying mechanisms","volume":"1864","author":"Rizzo","year":"2018","journal-title":"Biochim Biophys. Acta Mol. Basis Dis."},{"issue":"12","key":"10.1016\/j.phrs.2024.107058_bib178","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102682","article-title":"Glucagon-like peptide-1 analog liraglutide leads to multiple metabolic alterations in diet-induced obese mice","volume":"298","author":"Park","year":"2022","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.phrs.2024.107058_bib179","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1172\/JCI75276","article-title":"The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss","volume":"124","author":"Secher","year":"2014","journal-title":"J. Clin. Investig."},{"issue":"3","key":"10.1016\/j.phrs.2024.107058_bib180","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s12020-019-02081-x","article-title":"Effects of glucagon-like peptide-1 analog liraglutide on the systemic inflammation in high-fat-diet-induced mice","volume":"66","author":"Sha","year":"2019","journal-title":"Endocrine"},{"issue":"2","key":"10.1016\/j.phrs.2024.107058_bib181","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.bbrc.2018.09.134","article-title":"Liraglutide protects non-alcoholic fatty liver disease via inhibiting NLRP3 inflammasome activation in a mouse model induced by high-fat diet","volume":"505","author":"Zhu","year":"2018","journal-title":"Biochem Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2024.107058_bib182","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.2147\/DDDT.S224688","article-title":"Liraglutide improves non-alcoholic fatty liver disease in diabetic mice by modulating inflammatory signaling pathways","volume":"13","author":"Luo","year":"2019","journal-title":"Drug Des. Devel Ther."},{"issue":"3","key":"10.1016\/j.phrs.2024.107058_bib183","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.cmet.2016.08.003","article-title":"iNKT Cells Induce FGF21 for thermogenesis and are required for maximal weight loss in GLP1 therapy","volume":"24","author":"Lynch","year":"2016","journal-title":"Cell Metab."},{"issue":"7","key":"10.1016\/j.phrs.2024.107058_bib184","doi-asserted-by":"crossref","first-page":"918","DOI":"10.2337\/db22-0745","article-title":"Liraglutide and exercise synergistically attenuate vascular inflammation and enhance metabolic insulin action in early diet-induced obesity","volume":"72","author":"Liu","year":"2023","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.phrs.2024.107058_bib185","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/1479164111404257","article-title":"A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-\/- mouse model","volume":"8","author":"Gaspari","year":"2011","journal-title":"Diab Vasc. Dis. Res."},{"key":"10.1016\/j.phrs.2024.107058_bib186","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2022.111560","article-title":"Liraglutide prevents high glucose induced HUVECs dysfunction via inhibition of PINK1\/Parkin-dependent mitophagy","volume":"545","author":"Zhang","year":"2022","journal-title":"Mol. Cell Endocrinol."},{"key":"10.1016\/j.phrs.2024.107058_bib187","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.618208","article-title":"Effect of liraglutide on cardiometabolic risk profile in people with coronary artery disease with or without type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Nowrouzi-Sohrabi","year":"2021","journal-title":"Front. Pharm."},{"issue":"2","key":"10.1016\/j.phrs.2024.107058_bib188","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/dom.14903","article-title":"Comparative effects of weight loss and incretin-based therapies on vascular endothelial function, fibrinolysis and inflammation in individuals with obesity and prediabetes: a randomized controlled trial","volume":"25","author":"Mashayekhi","year":"2023","journal-title":"Diabetes Obes. Metab."},{"issue":"1","key":"10.1016\/j.phrs.2024.107058_bib189","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-023-01765-z","article-title":"Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial","volume":"22","author":"Sandsdal","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"issue":"8","key":"10.1016\/j.phrs.2024.107058_bib190","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/cbf.3751","article-title":"Semaglutide (GLP-1 receptor agonist) stimulates browning on subcutaneous fat adipocytes and mitigates inflammation and endoplasmic reticulum stress in visceral fat adipocytes of obese mice","volume":"40","author":"Martins","year":"2022","journal-title":"Cell Biochem Funct."},{"key":"10.1016\/j.phrs.2024.107058_bib191","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1046130","article-title":"Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model","volume":"13","author":"Niu","year":"2022","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.phrs.2024.107058_bib192","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.bbrc.2022.07.034","article-title":"Single-cell transcriptome reveals effects of semaglutide on non-cardiomyocytes of obese mice","volume":"622","author":"Pan","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1 Pt A","key":"10.1016\/j.phrs.2024.107058_bib193","article-title":"Obesity, cardiovascular disease, and the promising role of semaglutide: insights from the SELECT trial","volume":"49","author":"Irfan","year":"2023","journal-title":"Curr. Probl. Cardiol."},{"issue":"14","key":"10.1016\/j.phrs.2024.107058_bib194","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"Jama"},{"issue":"2","key":"10.1016\/j.phrs.2024.107058_bib195","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial","volume":"327","author":"Rubino","year":"2022","journal-title":"Jama"},{"issue":"2","key":"10.1016\/j.phrs.2024.107058_bib196","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/apt.15316","article-title":"Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and\/or obesity","volume":"50","author":"Newsome","year":"2019","journal-title":"Aliment Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.phrs.2024.107058_bib197","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s13300-022-01226-y","article-title":"Effect of oral semaglutide on cardiovascular parameters and their mechanisms in patients with type 2 diabetes: rationale and design of the semaglutide anti-atherosclerotic mechanisms of action study (SAMAS)","volume":"13","author":"Jani\u0107","year":"2022","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.phrs.2024.107058_bib198","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105782","article-title":"Anti-diabetic drugs and weight loss in patients with type 2 diabetes","volume":"171","author":"Lazzaroni","year":"2021","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.phrs.2024.107058_bib199","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-80894-x","article-title":"Dulaglutide exerts beneficial anti atherosclerotic effects in ApoE knockout mice with diabetes: the earlier, the better","volume":"11","author":"Sanada","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2024.107058_bib200","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.molimm.2019.09.021","article-title":"Glucagon-like peptide-1 receptor agonist dulaglutide prevents ox-LDL-induced adhesion of monocytes to human endothelial cells: an implication in the treatment of atherosclerosis","volume":"116","author":"Chang","year":"2019","journal-title":"Mol. Immunol."},{"issue":"10193","key":"10.1016\/j.phrs.2024.107058_bib201","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.phrs.2024.107058_bib202","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40265-020-01260-9","article-title":"Dulaglutide: a review in type 2 diabetes","volume":"80","author":"Scott","year":"2020","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.phrs.2024.107058_bib203","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1016\/j.numecd.2021.07.015","article-title":"Effects of GLP-1 receptor agonists on myokine levels and pro-inflammatory cytokines in patients with type 2 diabetes mellitus","volume":"31","author":"Guarnotta","year":"2021","journal-title":"Nutr. Metab. Cardiovasc Dis."},{"issue":"6","key":"10.1016\/j.phrs.2024.107058_bib204","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.tem.2020.02.006","article-title":"How May GIP Enhance the Therapeutic Efficacy of GLP-1?","volume":"31","author":"Samms","year":"2020","journal-title":"Trends Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.phrs.2024.107058_bib205","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.phrs.2024.107058_bib206","doi-asserted-by":"crossref","DOI":"10.1172\/JCI146353","article-title":"GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice","volume":"131","author":"Samms","year":"2021","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.phrs.2024.107058_bib207","doi-asserted-by":"crossref","DOI":"10.1111\/dom.15269","article-title":"Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis","author":"Hankosky","year":"2023","journal-title":"Diabetes Obes. Metab."},{"issue":"12","key":"10.1016\/j.phrs.2024.107058_bib208","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1111\/dom.15269","article-title":"Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the SURMOUNT-1 trial","volume":"25","author":"Hankosky","year":"2023","journal-title":"Diabetes Obes. Metab."},{"issue":"3","key":"10.1016\/j.phrs.2024.107058_bib209","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41591-022-01707-4","article-title":"Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis","volume":"28","author":"Sattar","year":"2022","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.phrs.2024.107058_bib210","article-title":"Tirzepatide versus semaglutide once weekly in type 2 diabetes","volume":"386","author":"Santulli","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.phrs.2024.107058_bib211","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s13300-020-00981-0","article-title":"The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: The SURPASS clinical trials","volume":"12","author":"Min","year":"2021","journal-title":"Diabetes Ther."},{"issue":"12","key":"10.1016\/j.phrs.2024.107058_bib212","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41574-018-0120-3","article-title":"Testing a novel dual receptor agonist for treatment of type 2 diabetes mellitus","volume":"14","author":"Greenhill","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"issue":"12","key":"10.1016\/j.phrs.2024.107058_bib213","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1111\/dom.14174","article-title":"The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes","volume":"22","author":"Wilson","year":"2020","journal-title":"Diabetes Obes. Metab."},{"issue":"2","key":"10.1016\/j.phrs.2024.107058_bib214","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1210\/clinem\/dgab722","article-title":"Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes","volume":"107","author":"Pirro","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.phrs.2024.107058_bib215","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/dom.14553","article-title":"The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: a post hoc analysis","volume":"24","author":"Wilson","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.phrs.2024.107058_bib216","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2018.00640","article-title":"Obesity, fat mass and immune system: role for Leptin","volume":"9","author":"Francisco","year":"2018","journal-title":"Front. Physiol."},{"key":"10.1016\/j.phrs.2024.107058_bib217","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.585887","article-title":"Leptin and Obesity: role and clinical implication","volume":"12","author":"Obradovic","year":"2021","journal-title":"Front. Endocrinol."},{"issue":"8","key":"10.1016\/j.phrs.2024.107058_bib218","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1210\/js.2019-00103","article-title":"Advanced lipoprotein analysis shows atherogenic lipid profile that improves after metreleptin in patients with lipodystrophy","volume":"3","author":"Kinzer","year":"2019","journal-title":"J. Endocr. Soc."},{"key":"10.1016\/j.phrs.2024.107058_bib219","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.12688\/f1000research.20150.1","article-title":"Recent advances in understanding lipodystrophy: a focus on lipodystrophy-associated cardiovascular disease and potential effects of leptin therapy on cardiovascular function","volume":"8","author":"Bruder-Nascimento","year":"2019","journal-title":"F1000Res"},{"issue":"2","key":"10.1016\/j.phrs.2024.107058_bib220","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s13679-018-0300-4","article-title":"Future pharmacotherapy for obesity: new anti-obesity drugs on the horizon","volume":"7","author":"Srivastava","year":"2018","journal-title":"Curr. Obes. Rep."},{"issue":"1","key":"10.1016\/j.phrs.2024.107058_bib221","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/cen.12980","article-title":"Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy","volume":"85","author":"Chan","year":"2016","journal-title":"Clin. Endocrinol."},{"issue":"9","key":"10.1016\/j.phrs.2024.107058_bib222","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/oby.2009.184","article-title":"Enhanced weight loss with pramlintide\/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy","volume":"17","author":"Ravussin","year":"2009","journal-title":"Obesity"},{"issue":"3","key":"10.1016\/j.phrs.2024.107058_bib223","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1124\/pr.115.010629","article-title":"Amylin: pharmacology, physiology, and clinical potential","volume":"67","author":"Hay","year":"2015","journal-title":"Pharmacol. Rev."},{"issue":"12","key":"10.1016\/j.phrs.2024.107058_bib224","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1517\/14712598.2011.619974","article-title":"Novel strategy for the use of leptin for obesity therapy","volume":"11","author":"Tam","year":"2011","journal-title":"Expert Opin. Biol. Ther."},{"issue":"10317","key":"10.1016\/j.phrs.2024.107058_bib225","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/S0140-6736(21)01751-7","article-title":"Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial","volume":"398","author":"Lau","year":"2021","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.phrs.2024.107058_bib226","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.jacc.2023.02.018","article-title":"Phase 2b randomized trial of the oral PCSK9 inhibitor MK-0616","volume":"81","author":"Ballantyne","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"issue":"8","key":"10.1016\/j.phrs.2024.107058_bib227","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1038\/s41591-022-01936-7","article-title":"Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial","volume":"28","author":"Nicholls","year":"2022","journal-title":"Nat. Med"},{"issue":"12","key":"10.1016\/j.phrs.2024.107058_bib228","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.jacc.2022.01.023","article-title":"Resmetirom (MGL-3196) in Patients With Heterozygous Familial Hypercholesterolemia","volume":"79","author":"Hovingh","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"issue":"16","key":"10.1016\/j.phrs.2024.107058_bib229","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/j.jacc.2023.02.038","article-title":"Familial hypercholesterolemia: challenges for a high-risk population: JACC focus seminar 1\/3","volume":"81","author":"Choi","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2024.107058_bib230","article-title":"New therapies for obesity","author":"Papamargaritis","year":"2022","journal-title":"Cardiovasc. Res."},{"issue":"9","key":"10.1016\/j.phrs.2024.107058_bib231","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.3390\/nu15092095","article-title":"A scoping review of the relationship between intermittent fasting and the human gut microbiota: current knowledge and future directions","volume":"15","author":"Popa","year":"2023","journal-title":"Nutrients"},{"issue":"12","key":"10.1016\/j.phrs.2024.107058_bib232","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med"},{"issue":"10118","key":"10.1016\/j.phrs.2024.107058_bib233","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","article-title":"Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial","volume":"391","author":"Ridker","year":"2018","journal-title":"Lancet"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661824000021?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661824000021?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:48:24Z","timestamp":1760914104000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661824000021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":233,"alternative-id":["S1043661824000021"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2024.107058","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting systemic inflammation in metabolic disorders. A therapeutic candidate for the prevention of cardiovascular diseases?","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2024.107058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107058"}}